Abstract O214 – Table 1. Virological primary outcomes
Without M184V/I, N = 1489 (%) | With M184 V/I, N = 137 (%) | |
---|---|---|
Virological failure (VF) | 17 (1.14) | 4 (3) |
a) 1st definition: 2x HIV‐RNA >50 copies/mL | 10 (0.67) | 1 (0.73) |
b) 2nd definition: 1x HIV‐RNA >50 copies/mL + ABC/3TC/DTG stop | 7 (0.47) | 3 (2.1) |
Treatment (ABC/3TC/DTG) discontinued for reasons other than VF | 232 (15.58) | 14 (10.22) |
Virological blipsa (VB) had at least one blip during ABC/3TC/DTG | 63 (4.2) | 12 (8.8) |
VB, median copies/mL (IQR) | 79 (62 to 122) | 72 (58 to 154) |
VF incidence (per 1000 person‐years) | 13.56 (8.43 to 21.83) | 29.8 (11.17 to 79.39) |
avirological blips: any viral load measurement >50 copies/mL, with viral load subsequently undetectable.